A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

NCT04991506 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Neoplasms
Malignant Tumor

Interventions

DRUG: ES102
DRUG: JS001

Sponsor

Elpiscience Biopharma, Ltd.

Collaborators

[object Object]